Drug profile · INN
biperiden lactate
AKINETON
biperiden lactate (AKINETON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — biperiden lactate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
biperiden lactate (AKINETON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is biperiden lactate?
biperiden lactate (AKINETON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for biperiden lactate?
AKINETON is a marketed brand name for biperiden lactate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of biperiden lactate?
biperiden lactate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.